Le Lézard
Classified in: Health, Business, Covid-19 virus
Subject: VEN

Montana based Inimmune awarded $2M SBIR to advance Vaccine Technologies


MISSOULA, Mont., July 1, 2020 /PRNewswire/ -- Inimmune Corporation, a biotechnology company located in Missoula, MT, was recently awarded a $2 M grant from the National Institute for Allergy and Infectious Diseases (NIAID) under its Small Business Innovation Research (SBIR) Direct to Phase II program to advance a novel adjuvant and delivery system for vaccines.

Adjuvants are vaccine components that stimulate and direct the immune system to enhance immunity to a vaccine. Through this SBIR grant, Inimmune will advance a proprietary synthetic vaccine adjuvant through innovative formulation and delivery technologies. The team will advance a stable and safe adjuvant delivery platform that elicits strong immune responses against a variety of infectious diseases, including COVID-19.

The lead researchers and co-principal investigators on this award, Drs. Shannon Miller and David Burkhart, are excited to lead the effort at Inimmune to complete this research and develop a new adjuvant system ready for clinical evaluation at the end of the two year contract. Dr. Miller, an Investigator and immunologist at Inimmune, stated, "It's exciting to work on projects that will advance the field of vaccine science and increase the availability of safe and effective vaccine adjuvants. Particularly given the current COVID-19 pandemic, it's great to see so much interest and investment in new vaccines and innovative technologies."

"This award builds on a strong adjuvant and immunotherapy pipeline at Inimmune and will help the company advance novel vaccines and treatments closer to testing in human clinical trials," stated Dr. David Burkhart, Inimmune co-founder and Chief Operating Officer.

Inimmune was co-founded in 2016 by a team of experienced industry researchers with the aim to harness the human immune system and create next generation immunotherapeutics. The team spent more than 20 years together working in Hamilton, MT prior to forming Inimmune in Missoula, MT. Their laboratories and offices are housed in the Montana Technology Enterprise Center (MonTEC).

For more information about Inimmune please visit www.Inimmune.com or contact Dr. Shannon Miller at [email protected] or Dr. David Burkhart at [email protected].

SOURCE Inimmune Corporation


These press releases may also interest you

at 13:26
In a bid to foster excellence and innovation in the healthcare industry, the esteemed Dr. Vidal Sheen proudly announces the launch of The Dr. Vidal Sheen Grant for Healthcare Students. With a robust focus on academic prowess, compassionate care, and...

at 13:17
Rexall is proud to unveil its first Pharmacist Care Walk-In Clinic in Barrie, Ontario on Friday, April 19. Located at 353 Duckworth Street, the clinic will offer personalized care to the community while providing immediate pharmacist treatment for...

at 13:13
Caring for communities extends beyond life-changing work in operating rooms and physician offices. Hartford HealthCare leadership today highlighted its corporate responsibility to environmental, social and economic sustainability in announcing its...

at 13:04
Concept Medical, a pioneer in innovative drug delivery technologies, proudly announces the commencement of its groundbreaking IDE clinical study, "MAGICAL-ISR" using MagicTouch ? Sirolimus drug coated balloon (DCB), for the management of in-stent...

at 12:30
The American College of Physicians (ACP) today released an update of its 2017 guideline with clinical recommendations for the use of newer pharmacological treatments of adults with Type 2 diabetes. The clinical guideline is based on the best...

at 12:10
Pieris Pharmaceuticals, Inc. today announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024. The Company's...



News published on and distributed by: